Loading…
Back To Schedule
Thursday, June 28 • 9:00am - 10:00am
#408: Innovative Funding Models for Novel Therapeutics

Sign up or log in to save this to your schedule, view media, leave feedback and see who's attending!

Tweet Share
Component Type: Forum
Level: Intermediate
CE: CME 1.00; IACET 1.00; RN 1.00

In the pharmaceutical and biotech industry today the scope for and the breadth of stakeholders is expanding. Today’s development networks are emerging as consortiums that freely share learnings and experiences in order to make the best therapeutic development strategies. Yet, there is still more to do to identify and leverage our available knowledge networks. In this forum we will focus on strategies to best collaborate for novel therapeutic development.

Additionally this forum will also cover specific product investing. Unlike healthcare technology, most angel investors categorically dismiss medical product investing – especially for drug products. There are ways to bridge this gap through better preparation and understanding. In this forum we will also discuss common threads of deals angels invest in, the ones they don’t and how they make those decisions. Items such as the product, the team, deal structure, expected return, time to return, drugs vs. devices, regulatory strategy and life cycle management.

Learning Objectives

Discuss the thinking of angel investors from a large angel investing syndicate; Describe how to prepare your company for investor pitching; Evaluate the quality of interaction of stakeholders in cure-based development; Assess quality of those interactions of stakeholders in their own environment; Recognize the importance of fostering an environment of innovation and entrepreneurship.

Chair

Dan Tierno, MA, MBA

Speaker

The Responsibility Industry, Agencies, and Early Education Own in Cure-Model Based Therapeutics
Dan Tierno, MA, MBA

What Angel Investors Think About Medical Product Investing
David Vulcano, MBA

Do You Really Need a Clinical Trial, Now?
Steve Scott, RN


Speakers
avatar for Steve Scott

Steve Scott

Independent Clinical Consultant, ResearchwoRx
Steve has worked in the clinical trial industry for 26 years. He began as a research nurse in emergency and trauma at Vanderbilt in Nashville. He was a CRA and a Senior Manager of Field Operations at Clinimetrics for 15 years and started ResearchwoRx, an independent consulting business... Read More →
avatar for Dan Tierno

Dan Tierno

Associate Director, Global Clinical Data Sciences and Analytics, Bayer
Mr. Dan Tierno has over 20 years of experience in the pharmaceutical and biotech industry, specializing in drug development, data sciences and analytics for clinical trials, and commercialization of novel small molecule and cell based therapeutics. Mr. Tierno has spoken on training... Read More →
avatar for David Vulcano

David Vulcano

Vice President, Clinical Research Compliance & Integrity, Hospital Corporation of America (HCA)
David is a well-known leader in the clinical research industry through numerous associations, boards and initiatives. Among other things he is currently employed by HCA, the largest private healthcare provider in the United States, as the Responsible Executive for Clinical Research... Read More →

Thursday June 28, 2018 9:00am - 10:00am
Room 206AB Boston Convention and Exhibition Center 415 Summer Street, Boston, MA 02210 USA
  06: PreClin Dev-EarlyPhaseCR, Forum